₹4,566.9
▼ -131.07 -2.79%
18 Jul 2026
NSE Listed
Pfizer Ltd. (PFIZER)
Volume: 32,731Avg Vol 1W: 27,600Avg Vol 1M: 32,163.752W Range:₹4,360.1₹5,873.5
Key Ratios
Checked 6h agoMarket Cap₹20,899 Cr
Current Price₹4,566.9
Previous Close₹4,697.97
High / Low (52w)₹5,873.5 / ₹4,360.1
Volume32,731
Avg Vol (1W)27,600
Avg Vol (1M)32,163.7
Stock P/E104.55
Book Value₹918.71
Dividend Yield164%
ROE17.19%
ROA14.68%
Revenue (TTM)₹2,708 Cr
Revenue Growth—
Profit Margin28.67%
Total Debt—
Shares Outstanding5 Cr
Face Value₹10
EPS (TTM)₹165.84
P/B4.97
Debt / Equity0
50 DMA₹4,574.16
200 DMA₹4,843.75
Day change-2.79%
Price Chart
₹4,566.9▼ 14.15% · 1Y
2025-07-182026-07-17
20-day avg volume: 32K shares
Pros
- Healthy return on equity of 17.2%.
- Pays a dividend yield of 164.0%.
- Company is almost debt-free.
Cons
- Stock trades at a high P/E of 105.
Quarterly Results
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹563 Cr | ₹589 Cr | ₹538 Cr | ₹592 Cr | ₹603 Cr | ₹642 Cr | ₹645 Cr | ₹629 Cr |
| EBITDA | ₹205 Cr | ₹217 Cr | ₹174 Cr | ₹256 Cr | ₹263 Cr | ₹258 Cr | ₹252 Cr | ₹262 Cr |
| Net Profit | ₹151 Cr | ₹158 Cr | ₹128 Cr | ₹331 Cr | ₹192 Cr | ₹189 Cr | ₹142 Cr | ₹200 Cr |
| EPS | — | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2,249 Cr | ₹2,336 Cr | ₹2,320 Cr | ₹2,674 Cr | ₹2,526 Cr | ₹2,374 Cr | ₹2,454 Cr | ₹2,708 Cr |
| EBITDA | ₹661 Cr | ₹653 Cr | ₹684 Cr | ₹783 Cr | ₹804 Cr | ₹754 Cr | ₹852 Cr | ₹1,034 Cr |
| Net Profit | ₹429 Cr | ₹509 Cr | ₹498 Cr | ₹613 Cr | ₹624 Cr | ₹551 Cr | ₹768 Cr | ₹722 Cr |
| EPS | 93.78 | 111.28 | 108.77 | 133.89 | 136.38 | 120.51 | 167.79 | 157.92 |
Balance Sheet
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹3,940 Cr | ₹4,405 Cr | ₹3,266 Cr | ₹3,901 Cr | ₹4,001 Cr | ₹4,229 Cr | ₹4,911 Cr | ₹4,922 Cr |
| Total Liabilities | ₹929 Cr | ₹1,010 Cr | ₹873 Cr | ₹1,036 Cr | ₹793 Cr | ₹633 Cr | ₹694 Cr | ₹719 Cr |
| Equity | ₹3,011 Cr | ₹3,395 Cr | ₹2,393 Cr | ₹2,864 Cr | ₹3,207 Cr | ₹3,596 Cr | ₹4,217 Cr | ₹4,203 Cr |
| Total Debt | — | — | — | — | — | — | — | — |
Cash Flow
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating | ₹536 Cr | ₹631 Cr | ₹893 Cr | ₹658 Cr | ₹411 Cr | ₹816 Cr | ₹953 Cr |
| Investing | ₹1,530 Cr | ₹-469 Cr | ₹-575 Cr | ₹-36 Cr | ₹54 Cr | ₹-71 Cr | ₹-562 Cr |
| Financing | ₹-164 Cr | ₹-1,571 Cr | ₹-181 Cr | ₹-346 Cr | ₹-235 Cr | ₹-205 Cr | ₹-798 Cr |
| Free Cash Flow | ₹536 Cr | ₹631 Cr | ₹893 Cr | ₹658 Cr | ₹411 Cr | ₹816 Cr | ₹953 Cr |
Shareholding
Promoter 63.92% Institutions 19.71% Public 16.37%
Efficiency & Working Capital
ROCE23%
Interest Coverage0
Dividend Payout—
Debtor Days26 d
Inventory Days68 d
Payable Days31 d
Cash Conversion Cycle64 d
Working Capital Days95 d
Shareholding Details
As of 2026-06-30
Promoter63.9%
FII1.7%
DII17.8%
Institutions19.4%
Public16.6%
Promoter Pledge0%
No. of Shareholders1,02,478
Shareholding Pattern
Quarterly — figures in %. Latest 12 quarters.
| Period | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 63.9% | 63.9% | 63.9% | 63.9% | 63.9% | 63.9% | 63.9% | 63.9% | 63.9% | 63.9% | 63.9% | 63.9% |
| FIIs | 2.8% | 3% | 3.3% | 3.2% | 3.5% | 2.7% | 2.2% | 2.4% | 2.6% | 2.7% | 2.8% | 1.7% |
| DIIs | 15% | 15.1% | 15.3% | 15.8% | 16% | 16.8% | 17.1% | 17.2% | 17.1% | 17% | 16.9% | 17.8% |
| Public | 18.2% | 17.9% | 17.4% | 17% | 16.5% | 16.5% | 16.8% | 16.5% | 16.4% | 16.3% | 16.4% | 16.6% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 1,16,948 | 1,12,456 | 1,09,214 | 1,06,098 | 98,824 | 1,05,015 | 1,08,261 | 1,03,222 | 1,03,480 | 1,00,933 | 99,545 | 1,02,478 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202603 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Pfizer East India B V | Shareholding of Promoter and Promoter Group | 39.8% | 1.82 Cr |
| Wyeth Llc | Shareholding of Promoter and Promoter Group | 12.3% | 56,17,707 |
| Nippon Life India Trustee Ltd | Public Shareholding | 4.2% | 19,06,535 |
| Life Insurance Corporation Of India | Public Shareholding | 3.7% | 17,09,223 |
| Wyeth Holdings Corporation | Shareholding of Promoter and Promoter Group | 3.6% | 16,30,164 |
| Icici Prudential Fund | Public Shareholding | 3.3% | 15,14,012 |
| Warner-lambert Company Llc | Shareholding of Promoter and Promoter Group | 2.6% | 11,87,163 |
| Quant Mutual Fund | Public Shareholding | 2.2% | 10,16,315 |
| Atul Limited | Public Shareholding | 2.1% | 9,58,927 |
| Parke, Davis & Company Llc | Shareholding of Promoter and Promoter Group | 2.1% | 9,55,733 |
| John Wyeth & Brother Ltd | Shareholding of Promoter and Promoter Group | 1.9% | 8,82,000 |
| Pharmacia Corporation | Shareholding of Promoter and Promoter Group | 1.7% | 7,83,941 |
Promoter Pledges
| Holder | Pledged Shares | % of Holding | As of |
|---|---|---|---|
| Wyeth Holdings Corporation | 0 | 0% | 2026-06-30 |
| John Wyeth & Brother Ltd | 0 | 0% | 2026-06-30 |
| Warner-lambert Company Llc | 0 | 0% | 2026-06-30 |
| Wyeth Llc | 0 | 0% | 2026-06-30 |
| Parke, Davis & Company Llc | 0 | 0% | 2026-06-30 |
| Pfizer East India B V | 0 | 0% | 2026-06-30 |
| Pharmacia Corporation | 0 | 0% | 2026-06-30 |
| Nippon Life India Trustee Ltd | 0 | 0% | 2026-06-30 |
| Quant Mutual Fund | 0 | 0% | 2026-06-30 |
| Icici Prudential Fund | 0 | 0% | 2026-06-30 |
| Life Insurance Corporation Of India | 0 | 0% | 2026-06-30 |
| Atul Limited | 0 | 0% | 2026-06-30 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| Pradip Shah | Chairman(Non Exe)&Dir(Non-Ind) | 2026 |
| MEENA GANESH | Independent Non Exe. Director | 2026 |
| L Krishnakumar | Independent Non Exe. Director | 2026 |
| Sonia Singh | Independent Non Exe. Director | 2026 |
| Meenakshi Nevatia | Managing Director & CEO | 2026 |
| Amit Agarwal | Executive Director - Finance / WTD / CFO | 2026 |
| P. Rengan | Executive Director / Whole Time Director | 2026 |
| Prajeet Nair | CS / Director - Corporate Services | 2026 |
Segments — Product
| Segment | Revenue | Share |
|---|---|---|
| Pharmaceuticals | ₹915 Cr | 87.2% |
| Services | ₹0 Cr | 0% |
| Others | ₹134 Cr | 12.8% |
Segments — Geography
| Region | Revenue | Share |
|---|---|---|
| India | ₹2,423 Cr | 96.2% |
| outside of India | ₹96 Cr | 3.8% |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2026 | ₹10 | 53 | 46 | 46 |
Corporate Actions
| Type | Date | Value | Remark |
|---|---|---|---|
| dividend | 2026-07-17 | ₹75 (750%) | Final |
| forthcoming | 2026-07-17 | Dividend (75/- per share) | Final |
| dividend | 2025-07-09 | ₹35 (350%) | Final |
| dividend | 2025-07-09 | ₹100 (1000%) | Special 1 |
| dividend | 2025-07-09 | ₹30 (300%) | Special 2 |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2026 | 849 | 0 | 0 | 17 | 485 | 1,352 |
| 2026 | 703 | 0 | 0 | 17 | 485 | 1,205 |
| 2026 | 146 | 0 | 0 | 0 | 0 | 146 |
Substantial Acquisitions (SAST)
1 disclosure(s)
Market28/04/2022 · 9,30,573
Company Information
🌐 www.pfizerindia.com ↗
📍 The Capital 1802/1901 Plot-C70, G Bl Bandra Kurla Cpx Bandra-E, Mumbai, Maharashtra, 400051
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search